{"id":412396,"date":"2021-01-11T16:04:20","date_gmt":"2021-01-11T21:04:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412396"},"modified":"2021-01-11T16:04:20","modified_gmt":"2021-01-11T21:04:20","slug":"adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/","title":{"rendered":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics"},"content":{"rendered":"
\n

\n Multi-year, pan-portfolio deal extends Adaptive\u2019s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology<\/em>
\n \n <\/p>\n

\n This transaction highlights the value of immune receptor data generated by Adaptive\u2019s proprietary immune medicine platform<\/em>\n <\/p>\n

SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT),\u00a0a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive\u2019s proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca\u2019s oncology portfolio. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Under this collaboration, AstraZeneca will provide biological samples from patients with cancer; Adaptive will sequence these samples and deliver TCR-antigen mapping data using its growing and dynamic clinical immunomics database of more than 58 billion immune cell receptors and thousands of antigens. This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions. Additionally, mapping of unique TCRs to antigens at scale can provide powerful information regarding the potential for early and accurate detection of a disease and the specificity of a given patient\u2019s immune response to therapy.<\/p>\n

\u201cWe continue to demonstrate that specific T-cell immune receptor data can be utilized to inform the diagnosis and treatment for most diseases,\u201d said Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies. \u201cWe are thrilled to partner with AstraZeneca to realize the value of antigen-specific T-cell response data across their portfolio of transformative cancer medicines.\u201d<\/p>\n

Adaptive will receive from AstraZeneca quarterly payments plus sequencing and data mapping fees. In addition, AstraZeneca has an option to enter into a separate agreement with Adaptive for the development and commercialization of a companion diagnostic or therapeutic application based on T-MAP data. Specific financial terms of the agreement will not be disclosed.<\/p>\n

The scope of this non-exclusive, pan-portfolio oncology collaboration may be expanded to cover additional therapeutic areas, including autoimmunity and infectious diseases.<\/p>\n

\n About Adaptive <\/strong>
\n
Adaptive Biotechnologies\u00a0is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature\u2019s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com<\/a> and follow us on www.twitter.com\/adaptivebiotech<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements.\u00a0These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n

\n ADAPTIVE MEDIA<\/strong>
\n
Beth Keshishian
917-912-7195
media@adaptivebiotech.com<\/a><\/p>\n

\n ADAPTIVE INVESTORS<\/strong>
\n
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil,\u00a0Gilmartin Group
investors@adaptivebiotech.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Multi-year, pan-portfolio deal extends Adaptive\u2019s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive\u2019s proprietary immune medicine platform SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT),\u00a0a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive\u2019s proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca\u2019s oncology portfolio. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under this collaboration, AstraZeneca will provide biological samples from patients with … <\/p>\n

Continue reading “Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412396","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Multi-year, pan-portfolio deal extends Adaptive\u2019s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive\u2019s proprietary immune medicine platform SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT),\u00a0a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive\u2019s proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca\u2019s oncology portfolio. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under this collaboration, AstraZeneca will provide biological samples from patients with … Continue reading "Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T21:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics\",\"datePublished\":\"2021-01-11T21:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/\"},\"wordCount\":729,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/\",\"name\":\"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=\",\"datePublished\":\"2021-01-11T21:04:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk","og_description":"Multi-year, pan-portfolio deal extends Adaptive\u2019s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive\u2019s proprietary immune medicine platform SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT),\u00a0a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational collaboration with AstraZeneca (LSE\/STO\/Nasdaq: AZN) to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive\u2019s proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca\u2019s oncology portfolio. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under this collaboration, AstraZeneca will provide biological samples from patients with … Continue reading \"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T21:04:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics","datePublished":"2021-01-11T21:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/"},"wordCount":729,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/","name":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=","datePublished":"2021-01-11T21:04:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc5MiMzOTEyMjc5IzIxNzcxODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-cancer-antigens-to-potentially-inform-the-development-of-novel-diagnostics-and-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412396"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412396\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}